Drugs of Tomorrow HIV - Managing Portfolio Growth During Sector Slowdown

Introduction:

The HIV sector is experiencing a slowdown following high growth rates during its early years, but the R&D pipeline is set to deliver products onto the market to 2010 with the potential to fundamentally alter the competitive dynamics of the current market. This Pipeline Analysis provides in-depth knowledge of potential future market leaders and the strategies adopted by the product developers. 

Scope:

* Analysis of the R&D pipeline for HIV, covering sales forecasts for late phase II & III stage products through to 2010. 

* Analysis of strategic aspects of trial design in HIV, launch strategies and company portfolio composition. 

Report Highlights:

Current market leaders are reappraising their positioning within the HIV market, with direct impacts on the level and composition of investment in pipeline portfolios.  

The HIV sector is experiencing a slowdown following high growth rates during its formative years, leading to negative growth rates for three of the seven HIV portfolios currently on the market 

New market entrant in the HIV sector is faced with a major choice between usurping existing market share by substituting a current HAART component, or attempting to create additional market potential.  

Reasons to Purchase:

* What can the pharmaceutical industry do to improve the capture of non-diagnosed patients? 

* Understand the factors involved in the development of a compound that yield the best potential for subsequent commercial success 

* Analyze the commercial impact of the approval of late stage pipeline products on the HIV market 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a172